Dr. Bergstein is Chief Executive Officer and Founder of Stemline Therapeutics. He led Stemline through multiple rounds of private financing and ultimately its successful IPO and subsequent follow-on offering, raising over $100 million as a public company.
Prior to founding Stemline, Dr. Bergstein was Medical Director of Access Oncology, Inc., a
clinical stage oncology-focused biotechnology company where he was a key member of a small team responsible for the acquisition and development of the company’s clinical stage assets and ultimately the sale of the company.
Previously, he was a senior biopharmaceuticals analyst at a Wall Street-based firm that advised mutual funds and hedge funds on investments in public companies with late clinical stage assets.
Dr. Bergstein received a B.A. in Mathematics from the University of Pennsylvania. He subsequently earned an M.D. from the Mount Sinai Medical Center where he was named to the Alpha Omega Alpha Medical Honor Society, was recipient of the Merck Award for Clinical Excellence, and subsequently completed a general surgery internship. He was then named the Jerome A. Urban post-doctoral fellow at Cornell University Medical College where he published work concerning oncogenes in breast cancer.
Dr. Bergstein then completed a residency in internal medicine and a clinical fellowship in hematology-medical oncology at the New York Presbyterian Hospital-Weill Medical College of Cornell University, where he is currently a voluntary faculty member.
How old is Dr. Ivan Bergstein?
How do I contact Dr. Ivan Bergstein?
Has Dr. Ivan Bergstein been buying or selling shares of Stemline Therapeutics?
Who are Stemline Therapeutics' active insiders?
